Clinical Trials Update: April 19, 2007

Bladder Cancer Endometriosis Genital Herpes

(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:

Bladder Cancer

The purpose of this study is to test an investigational drug, vinflunine, in combination with gemcitabine in patients with transitional cell carcinoma who cannot be treated with cisplatin.

This study will help to determine whether vinflunine in combination with gemcitabine extends the time period of tumor growth more than gemcitabine alone.

Patients must be men or women 18 years or older with a clinical diagnosis of transitional cell carcinoma of the urothelium that is locally advanced or metastatic. Additional criteria apply.

The research site is in Macon, Ga.

More information

Please see



This is a clinical study to evaluate an investigational oral pill compared to depo-subQ provera 104 for the treatment of endometriosis.

Qualified participants will receive study-related examinations and diagnostic procedures including a Pap smear, laboratory tests, and bone mineral density assessments, and the study medication at no cost.

Travel expenses to and from the clinical site may be reimbursed. To qualify you must be between 18 and 49 years old, have moderate to severe pelvic pain due to endometriosis and have been surgically (laparoscopy or laparotomy) diagnosed with endometriosis within the past 7 years and have recurrent or persistent endometriosis symptoms. Additional criteria apply.

The research site is in Fargo, N.D.

Please see


Genital Herpes

This is a study of an oral medication to help with genital herpes outbreaks.

The study will last approximately six months and 13 office visits. Patients of both genders will be accepted, and they must be 18 or older and diagnosed with genital herpes.

Candidates for this study should not have have any HIV, cancer or either hepatitis B or C. Other criteria may apply.

The research site is in Pembroke Pines, Fla.

More information

Please see

Copyright 2007 Thomson CenterWatch. All rights reserved.

Consumer News